A randomised, multicenter, phase III study of Erlotinib versus observation in patients with no evidence of disease progression after first line, platinum-based chemotherapy in high-risk Stage I and Stage II-IV ovarian epithelial, primary peritoneal, or fallopian tube cancer.

Trial Profile

A randomised, multicenter, phase III study of Erlotinib versus observation in patients with no evidence of disease progression after first line, platinum-based chemotherapy in high-risk Stage I and Stage II-IV ovarian epithelial, primary peritoneal, or fallopian tube cancer.

Completed
Phase of Trial: Phase III

Latest Information Update: 17 Jun 2016

At a glance

  • Drugs Erlotinib (Primary)
  • Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Registrational; Therapeutic Use
  • Sponsors Roche
  • Most Recent Events

    • 23 Dec 2013 Results published in the Journal of Clinical Oncology.
    • 26 Aug 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 05 Jun 2012 Results presented at the 48th Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top